{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:09:21Z","timestamp":1790975361980,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Indeterminate thyroid cytology remains a major diagnostic challenge. Thyroid nodules classified as Bethesda category (BC) III and IV carry an intermediate risk of malignancy, and their management often involves a choice between active surveillance and diagnostic surgery. This study aimed to assess the prevalence of benign, low-risk, and malignant lesions in surgically treated patients with these nodules, and to identify factors associated with malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 618 patients with BC III or IV thyroid nodules, selected from 2,239 patients who underwent thyroid surgery between October 2022 and December 2025 at a Tertiary Referral Endocrine Surgery Centre in Krakow. Histopathology followed the 2022 WHO Classification of Thyroid Tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The distribution of tumor types differed significantly in both BCs III (n=365) and IV (n=253) nodules (both p&amp;lt;0.001), with benign lesions predominating (62.5% in BC III and 55.7% in BC IV), followed by malignant (30.4% and 32.8%) and low-risk lesions (7.1% and 11.5%), respectively. Younger age was associated with a higher risk of malignancy in both BC III (p=0.03) and BC IV (p=0.02). Sex was associated with lesion distribution in BC III (p = 0.016) but not BC IV (p = 0.06), and was not an independent predictor of malignancy. Tumor size \u22651 cm was associated with malignancy in BC IV (p=0.005), but not in BC III (p=0.35). Although age alone showed limited discriminative ability, multivariable analysis identified age &amp;lt;50 years as the only independent predictor of malignancy (adjusted OR 1.74; 95% CI 1.23\u20132.47; p=0.002) and lymph node metastasis (adjusted OR 4.56; 95% CI 1.19\u201317.53; p=0.03), while sex, chronic lymphocytic thyroiditis (CLT), and BC were not significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this surgical cohort of BC III and IV thyroid nodules, approximately one-third of lesions were malignant. Younger age was independently associated with malignancy, but its value as an isolated predictor was limited, and the overall discriminative performance of the multivariable model was modest. These findings may support individualized preoperative risk stratification; however, given the retrospective design and the selection of patients for surgery, they do not justify firm conclusions regarding the optimal extent of surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1859531","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:36:33Z","timestamp":1786941393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and predictors of malignancy in Bethesda III and IV thyroid nodules undergoing surgery"],"prefix":"10.3389","volume":"17","author":[{"given":"Anna","family":"Krzentowska","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Medical College, Andrzej Frycz Modrzewski Krakow University","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander J\u00f3zef","family":"Konturek","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, Faculty of Medicine, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Go\u0142kowski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Medical College, Andrzej Frycz Modrzewski Krakow University","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Merklinger-Grucha\u0142a","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Public Health, Medical College, Andrzej Frycz Modrzewski Krakow University","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Barczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, Faculty of Medicine, Jagiellonian University Medical College","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0500","article-title":"The 2017 Bethesda system for reporting thyroid cytopathology","volume":"27","author":"Cibas","year":"2017","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5603\/EP.a2022.0028","article-title":"Diagnosis and treatment of thyroid cancer in adult patients\u2014recommendations of Polish scientific societies and the National Oncological Strategy","volume":"73","author":"Jarz\u0105b","year":"2022","journal-title":"Endokrynol Pol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.1553","article-title":"Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach","volume":"37","author":"Jung","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2021.100250","article-title":"Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective","volume":"23","author":"Zahid","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12902-020-0530-9","article-title":"Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology","volume":"20","author":"Yaprak Bayrak","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.14712\/23362936.2022.22","article-title":"Malignancy rates in thyroid nodules classified as Bethesda III and IV; correlating fine needle aspiration cytology with histopathology","volume":"123","author":"Pereira","year":"2022","journal-title":"Prague Med Rep"},{"key":"B9","article-title":"Rates of Malignancy in cytology indeterminate thyroid nodules: a single center surgical series","volume":"25","author":"Baraf","year":"2023","journal-title":"Isr Med Assoc J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.12871","article-title":"Malignancy rates in thyroid nodules classified as Bethesda categories III and IV: retrospective data from a tertiary center","volume":"16","author":"Godoi Cavalheiro","year":"2017","journal-title":"Int J Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40463-021-00530-0","article-title":"Rate of Malignancy for thyroid nodules with AUS\/FLUS cytopathology in a tertiary care center - a retrospective cohort study","volume":"50","author":"Hathi","year":"2021","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76615","article-title":"Rates and predictors of Malignancy in Bethesda III and IV thyroid nodules: a prospective study","volume":"16","author":"Azzam","year":"2024","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1326134","article-title":"Ultrasonographic predictors of thyroid cancer in Bethesda III and IV thyroid nodules","volume":"15","author":"Alyusuf","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/dc.24248","article-title":"Ultrasound characteristics of thyroid nodules facilitate interpretation of the Malignant risk of Bethesda system III\/IV thyroid nodules and inform therapeutic schedule","volume":"47","author":"Li","year":"2019","journal-title":"Diagn Cytopathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247559","article-title":"Risk factors for Malignancy of thyroid nodules in patients undergoing thyroid resection","volume":"13","author":"Krzentowska","year":"2024","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.5858\/133.5.787","article-title":"Clinical outcomes for \u201csuspicious\u201d category in thyroid fine-needle aspiration biopsy: patient\u2019s sex and nodule size are possible predictors of Malignancy","volume":"133","author":"Raparia","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0650","article-title":"Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory","volume":"24","author":"Rosario","year":"2014","journal-title":"Thyroid"},{"key":"B18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/ajcp\/aqy109","article-title":"A proposal for separation of nuclear atypia and architectural atypia in Bethesda category III (AUS\/FLUS) based on differing rates of thyroid Malignancy","volume":"151","author":"Johnson","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21823","article-title":"Thyroid cytology-nuclear versus architectural atypia within the \u201catypia of undetermined significance\/follicular lesion of undetermined significance\u201d Bethesda category have significantly different rates of Malignancy","volume":"125","author":"Gan","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2024.31","article-title":"Thyroid fine-needle aspiration cytology: Malignancy rate in the category of indeterminate significant atypia\/indeterminate significant follicular lesion","volume":"44","author":"Terzi","year":"2024","journal-title":"Ann Saudi Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejso.2015.09.026","article-title":"Risk factors associated with Malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS\/FLUS)","volume":"42","author":"Kuru","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006564","article-title":"Ultrasound is helpful to differentiate Bethesda class III thyroid nodules: a PRISMA-compliant systematic review and meta-analysis","volume":"96","author":"Gao","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/1971400920983566","article-title":"Atypia of undetermined significance\/follicular lesions of undetermined significance: what radiologists need to know","volume":"34","author":"Ling","year":"2021","journal-title":"Neuroradiol J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.686849","article-title":"Surgical outcome and Malignant risk factors in patients with thyroid nodule classified as Bethesda category III","volume":"12","author":"Huang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081971","article-title":"Hashimoto\u2019s thyroiditis does not influence the Malignancy risk in nodules of category III in the Bethesda system","volume":"14","author":"S\u0142owi\u0144ska-Klencka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.745395","article-title":"Malignancy rate of Bethesda class III thyroid nodules based on the presence of chronic lymphocytic thyroiditis in surgical patients","volume":"12","author":"Cho","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6932-5","article-title":"Effect of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on Malignancy rates in thyroid nodules: how to counsel patients on extent of surgery","volume":"26","author":"Lindeman","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ando.2019.10.004","article-title":"Ultrasound and cytological characteristics of non-invasive follicular thyroid neoplasm with papillary-like nuclear features compared to papillary carcinomas","volume":"81","author":"Boursier","year":"2020","journal-title":"Ann Endocrinol (Paris)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5603\/ep.98488","article-title":"Ultrasound and cytopathological characteristics of thyroid tumours of uncertain Malignant potential - from diagnosis to treatment","volume":"75","author":"\u017by\u0142ka","year":"2024","journal-title":"Endokrynol Pol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203376","article-title":"Molecular testing and surgical outcomes in Bethesda III and IV thyroid nodules: a retrospective cohort study","volume":"17","author":"Payne","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cyt.12021","article-title":"Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology","volume":"24","author":"Dincer","year":"2013","journal-title":"Cytopathology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1859531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:36:36Z","timestamp":1786941396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1859531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":32,"alternative-id":["10.3389\/fendo.2026.1859531"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1859531","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1859531"}}